The short version
Liraglutide acts on a hormone signal called GLP-1. Saxenda is one product containing it. Its label explains who the medicine is intended for, what studies found, and the important risks.
Prescription status is product-specific. A recognized ingredient name does not make every preparation equivalent.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Liraglutide
- Entry name · The name used for this encyclopedia topic.
- Saxenda
- Brand name · A specific prescription product; the brand does not apply to every preparation.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Does the evidence match the preparation being discussed?
Check the exact product or substance, route, population and outcome. Ask which findings apply to your question, rather than assuming every product with the same ingredient name is equivalent.
Question to discuss · DailyMed · Saxenda prescribing information ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
The label describes human clinical studies. A product label is distinct from evidence supporting every claimed use of the underlying peptide.
SCALE · weight management (2015)
Summary based on: Published abstract
- Study design
- Randomized, double-blind, placebo-controlled trial; 56 weeks.
- Who was studied
- 3,731 adults without type 2 diabetes, with obesity or overweight and specified weight-related conditions.
- Route and preparation
- Subcutaneous injection of liraglutide, a specific study preparation.
- What was compared
- Liraglutide 3.0 mg daily versus placebo; both groups received lifestyle counseling.
- What researchers found
- Mean weight loss was 8.4 kg with liraglutide versus 2.8 kg with placebo. The estimated difference was −5.6 kg (95% confidence interval: −6.0 to −5.1), using an analysis carrying the last observed value forward for missing data.
- Adverse events and stopping treatment
- Nausea and diarrhea were common. Serious events occurred in 6.2% versus 5.0%; occurrence does not establish causation.
- What this leaves unanswered
- The selected population, follow-up and missing-data assumptions limit interpretation. Group averages are not individual predictions, and this trial does not cover every liraglutide product or use.
- Funding context
- The trial was funded by Novo Nordisk.
Research terms in everyday language ↗
Selected abstract-based SCALE summary included. Full-text appraisal, complete safety extraction and other study populations remain pending.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- GLP-1 receptor agonist
- Name variations
- Names you may see and important distinctions
- Source type
- U.S. prescribing information
- Reference jurisdiction
- United States
A receptor is a structure that receives a chemical signal. An agonist activates a receptor. The mechanism section of the linked label explains the relevant pathway in greater detail.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 7 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗